[go: up one dir, main page]

WO2001014369A3 - Process for the preparation of paroxetin.hcl - Google Patents

Process for the preparation of paroxetin.hcl Download PDF

Info

Publication number
WO2001014369A3
WO2001014369A3 PCT/EP2000/008176 EP0008176W WO0114369A3 WO 2001014369 A3 WO2001014369 A3 WO 2001014369A3 EP 0008176 W EP0008176 W EP 0008176W WO 0114369 A3 WO0114369 A3 WO 0114369A3
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
propan
acetic acid
paroxetin
hcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/008176
Other languages
French (fr)
Other versions
WO2001014369A2 (en
Inventor
David Crowe
David Alan Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to AU75101/00A priority Critical patent/AU7510100A/en
Publication of WO2001014369A2 publication Critical patent/WO2001014369A2/en
Publication of WO2001014369A3 publication Critical patent/WO2001014369A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Paroxetine hydrochloride is prepared by subjecting (-)-trans-1-benzyl-4-(4-fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl) piperidine hydrochloride to catalytic hydrogenation in the presence of a noble metal catalyst in a solvent system consisting of either a mixture of propan-2-o1 and a co-solvent, such as acetic acid, or a solvent other than propan-2-o1, preferably ethanol or methanol, optionally with a co-solvent such as water or acetic acid. Use of this solvent system reduces the amount of residual starting material in the paroxetine hydrochloride product.
PCT/EP2000/008176 1999-08-25 2000-08-18 Process for the preparation of paroxetin.hcl Ceased WO2001014369A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU75101/00A AU7510100A (en) 1999-08-25 2000-08-18 Novel process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9920146.9 1999-08-25
GBGB9920146.9A GB9920146D0 (en) 1999-08-25 1999-08-25 Novel process

Publications (2)

Publication Number Publication Date
WO2001014369A2 WO2001014369A2 (en) 2001-03-01
WO2001014369A3 true WO2001014369A3 (en) 2001-09-20

Family

ID=10859797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008176 Ceased WO2001014369A2 (en) 1999-08-25 2000-08-18 Process for the preparation of paroxetin.hcl

Country Status (3)

Country Link
AU (1) AU7510100A (en)
GB (1) GB9920146D0 (en)
WO (1) WO2001014369A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1640364A1 (en) * 2003-06-27 2006-03-29 Toray Fine Chemicals Co., Ltd. Process for producing nitrogenous heterocyclic compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001424A1 (en) * 1996-07-08 1998-01-15 Richter Gedeon Vegyészeti Gyár Rt. N-benzylpiperidine and tetrahydropyridine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001424A1 (en) * 1996-07-08 1998-01-15 Richter Gedeon Vegyészeti Gyár Rt. N-benzylpiperidine and tetrahydropyridine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S.BUDAVARI: "THE MERCK INDEX", 1996, MERCK & CO., NJ, XP002162714, 12 *

Also Published As

Publication number Publication date
AU7510100A (en) 2001-03-19
WO2001014369A2 (en) 2001-03-01
GB9920146D0 (en) 1999-10-27

Similar Documents

Publication Publication Date Title
EP1607387A3 (en) 3,4,4-trisubstituted piperidine derivatives and their use as opioid antagonists
IL128036A (en) Deoxynojirimycin derivatives comprising a polyclic alcohol group, pharmaceutical composition comprising a deoxynojirimycin derivative and uses thereof
CA2372339A1 (en) Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
EP2338891A3 (en) Method of forming hydromorphinone compositions
WO2001098268A3 (en) Piperidine amides as modulators of chemokine receptor activity
HK59397A (en) Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
CA2356871A1 (en) Synthesis of histamine dihydrochloride
EP0934920A3 (en) Preparation of hydrogenated compounds using noble metal Raney catalysts
ZA951331B (en) Process for the preparation of acetic acid by controlled oxidation of ethanol
CA2280310A1 (en) Nmda antagonist
AU6318700A (en) Supported ruthenium oxide catalyst, process for preparing supported ruthenium catalyst and process for producing chlorine
JP2002514648A5 (en)
CA2285242A1 (en) Mixture of primary fatty acids obtained from sugar cane wax
HUP0101143A3 (en) Pyridin-carboxylic acid derivatives as vitronectin receptor antagonists, process for producing them and pharmaceutical compositions containing them
WO2001014369A3 (en) Process for the preparation of paroxetin.hcl
HK1046404A1 (en) Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists
TW343194B (en) Improved method for the manufacture of felodipine
WO2002050133A3 (en) A method for preparing a supported catalyst system and its use in a polymerization process
EP0969007A3 (en) Method of making an aromatic chlorosilane compound by a hydrosilation reaction
EP1078912A3 (en) Process for the preparation of methyl cyclohexylpropionate
ATE224890T1 (en) SUBSTITUTED 1,2,3,4,5,6-HEXAHYDRO-2,6-METHANO-3-BENZAZOCINE-0-OLS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
JP2001247513A5 (en)
AU6752401A (en) Method for producing 2,3,4,6-tetramethyl mandelic acid and 2,3,4,6-tetramethyl mandelic acid acetate
DE50213160D1 (en) Process for the preparation of pyrroles
RU98109569A (en) METHOD FOR PRODUCING γ-AMINO-β-Phenylbutyric Acid Hydrochloride (Phenibutum)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP